Author: admin

  • New interstellar comet will keep a safe distance from Earth, NASA says

    New interstellar comet will keep a safe distance from Earth, NASA says

    By submitting, you consent that you are at least 18 years of age and to receive information about MPR’s or APMG entities’ programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.

    Continue Reading

  • 2025 British Grand Prix – McLAREN Practice Report "It's been nice to be back out on track in front of such a great crowd" – McLaren

    2025 British Grand Prix – McLAREN Practice Report "It's been nice to be back out on track in front of such a great crowd" – McLaren

    1. 2025 British Grand Prix – McLAREN Practice Report “It’s been nice to be back out on track in front of such a great crowd”  McLaren
    2. Fan favourite Norris on top in British GP practice  Dawn
    3. British Grand Prix: Lewis Hamilton says he can ‘dream of a strong weekend’ after challenging McLarens at Silverstone  BBC
    4. Liam Lawson hopeful of continued Racing Bulls progress: ‘It’s very close’  racingnews365.com
    5. A straightforward day  Ferrari

    Continue Reading

  • High winds alert scuppers Alanis Morissette show

    High winds alert scuppers Alanis Morissette show

    Alanis Morissette’s headline show at the Lytham Festival has been cancelled due to 40mph winds being forecast on the Fylde coast, organisers have confirmed.

    In a statement, organisers said the decision had been taken because of “adverse weather conditions”.

    A TK Maxx presents Lytham Festival spokesperson said: “The safety of our customers, staff and artists is our priority and increasing high winds mean it would not be safe to go ahead.

    “All customers will receive a full refund for tonight’s show. Please wait to hear from your ticket agent for further information.”

    The four-day music festival at Lytham Green, which runs until Sunday, was headlined on Thursday by legendary singer-songwriter Stevie Wonder.

    Rock band Kings of Leon had been due to open the festival, but had to cancel their appearance in May after lead singer Caleb Followill broke a bone in his heel in a “freak” accident.

    Canadian singer-songwriter Morissette shot to fame with her 1995 album Jagged Little Pill, which contained hits including Ironic, You Oughta Know, and Hand In My Pocket.

    Other acts who were due to play on Friday included Train – best known for their hit single Hey, Soul Sister – Greater Manchester indie band The Lottery Winners, and US singer Liz Phair.

    Justin Timberlake is due to headline on Saturday while Sunday’s closing night will feature dual headline slots from Simple Minds and Texas.

    Other acts booked for the four-day festival – expected to attract more than 100,000 music fans – include Corinne Bailey Rae, Jess Glynne and Cast.

    There will also be a special tribute to Welsh musician, songwriter and cancer campaigner Mike Peters of The Alarm.

    Continue Reading

  • Research highlights an increase in informal use of doxyPEP/PrEP among key populations in the Netherlands

    Research highlights an increase in informal use of doxyPEP/PrEP among key populations in the Netherlands

    New research analyzing an online survey of 1,633 respondents found 15% recent use of doxycycline post- and pre-exposure prophylaxis (doxyPEP/PrEP) among men who have sex with men (MSM), transgender and gender diverse people in the Netherlands according to a recent study published by Eurosurveillance. These data highlight an increase in the informal use of doxyPEP/PrEP, with 65% of the participants intending to use it in the future. Currently, doxyPEP/PrEP is not recommended or actively promoted by healthcare professionals in the Netherlands. Informal use i.e. without a prescription by a healthcare professional, could contribute to antimicrobial resistance (AMR) and changes in the microbiome.

    The use of doxyPEP has been shown to be an effective method in the prevention against sexually transmitted infections (STIs) in MSM, transgender and gender diverse persons. Clinical trials of doxyPEP have shown significant reductions in syphilis and chlamydia, with additional potential to reduce incidence of other bacterial STIs such as chlamydia and gonorrhea

    However, the public health implications of the widespread use of doxyPEP are subject to current debate. The administration of doxyPEP to specific individuals could prevent a substantial number of STIs and lower antibiotic use, particularly among those who repeatedly have STIs.

    Informal doxyPEP/PrEP use associated with HIV PrEP use, sexualized drug use and perception of safety

    As highlighted by this paper and an accompanying editorial by Lyons et al., the prescription of doxyPEP to many sexually active individuals poses the risk of a substantial population-level increase in overall antibiotic consumption and an increase in AMR.

    Teker et al. reviewed data from a cross-sectional study gathered from an online survey among MSM, transgender and gender diverse persons of 18 years of age or older. The survey focused on previous use of doxyPEP or doxyPrEP awareness and intention to use it. Participants were recruited through advertisements at the Centre for Sexual Health in Amsterdam, the Netherlands, as well as dating apps (Grindr), Instagram, Facebook, Facebook Messenger and targeted Instagram accounts.

    In the study, 23% of participants reported having ever used doxyPEP/PrEP and 15% reported having used doxyPEP/PrEP in the six months prior to the survey. Respondents informing about recent use were more likely to report living with HIV or frequently using oral HIV PrEP in the six months before taking the survey. They were also more likely to report a history of bacterial STIs, having a higher number of sexual partners, and a higher frequency of engaging in chemsex and in group sex during that period.

    Doxycycline was the most used antibiotic reported in this study, with 46% of the participants reporting using it recently as PEP, 29% of recent PEP users using it as PrEP and 25% using it as a combination of both. 

    Overall, the intention to use doxyPEP/PrEP was very high among the study population, with more than half of the participants (65%) expressing intention to use. More than two thirds of respondents (72%) were willing to pay for doxyPEP/PrEP if it became formally available, indicating a potential demand for the drug among the study population and beyond. 

    It was also found that doxyPEP/PrEP was primarily obtained from countries outside of the Netherlands or through prescriptions, with participants paying on average €30 for the drug.

    Additional determinants for both informal use of doxyPEP/PrEP and high intention to use included using oral HIV PrEP or living with HIV, receiving advice from others to use doxyPEP/PrEP and perceiving doxyPEP/PrEP as an effective and safe method of STI prevention.

    Potential antimicrobial resistance risks from lack of monitoring

    The impact of prophylactic antibiotic use on AMR was highlighted in the study as there are uncertainties regarding the long-term adverse effects of doxyPEP/PrEP use. Teker et al. emphasize the potential harms of doxycycline effectiveness and AMR risks, as summarised in previous studies including in the United States. 

    They also cite its potential effects on the gut microbiome, which need to be studied further. If doxyPEP is implemented in country-wide clinical guidance, it would be vital to monitor both individual and population-level resistance to doxycycline.

    Lack of awareness on the extent of informal use of doxyPEP/PrEP makes it difficult to monitor and implement appropriate public health stewardship. This leads to difficulties in detecting overuse, misuseand adverse effects including AMR development and effects on microbiome composition.

    Source:

    European Centre for Disease Prevention and Control (ECDC)

    Journal reference:

    Buhari, T., et al. (2025). Emergent informal use of doxycycline post- and pre-exposure prophylaxis among men who have sex with men and transgender and gender diverse people, the Netherlands, 2024. Eurosurveillance. doi.org/10.2807/1560-7917.ES.2025.30.26.2400707

    Continue Reading

  • Quantitative Vessel Tortuosity Shows Potential as Biomarker for Antiangiogenic Activity With Fruquintinib in mCRC

    Quantitative Vessel Tortuosity Shows Potential as Biomarker for Antiangiogenic Activity With Fruquintinib in mCRC

    mCRC | Image Credit:
    © Anatomy Insider
    – stock.adobe.com

    Quantitative vessel tortuosity (QVT), a noninvasive, radiomics-based imaging biomarker, was able to detect the antiangiogenic mechanism of action of fruquintinib (Fruzaqla) in patients with metastatic colorectal cancer (mCRC), according to data from a retrospective analysis of the phase 3 FRESCO-2 trial (NCT04322539) presented during the 2025 ESMO Gastrointestinal Cancer Congress.

    Results from the analysis demonstrated that patients in the fruquintinib group experienced a 70% decrease of vessel inflection in lung lesions from baseline to day 1 of cycle 3 (P < .0006). Additionally, patients in the fruquintinib arm experienced median reductions in vessel volume, torsion, curvature, and radius of 25% (P < .006), 15% (P < .05), 10% (P < .05), and 5% (P < .05), respectively, over the same time period. Conversely, patients in the placebo arm experienced a 30% increase in abnormal vessel branching at day 1 of cycle 3 compared with baseline (P < .05).

    “Significant changes in QVT features between patients in the fruquintinib and placebo arms were observed during the first assessment, demonstrating the early antiangiogenic action of fruquintinib,” Sara Lonardi, MD, chief of the Oncology 3 Unit of Veneto Institute of Oncology in Padua, Italy, and her coauthors wrote in the poster. “The observed differences in Delta QVT radiomic features…quantify the ability of fruquintinib to prevent the formation of a twisted, heterogeneous vasculature.”

    In November 2023, the FDA approved fruquintinib for the treatment of adult patients with mCRC who received previous treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.2 The regulatory decision was partially supported by prior data from FRESCO-2, which demonstrated that patients treated with the VEGFR inhibitor experienced a 34% reduction in the risk of death compared with those who received placebo (HR, 0.66; 95% CI, 0.55-0.80; P < .001).

    FRESCO-2 Study Design and Retrospective Analysis Methods

    FRESCO-2 was a global, double-blind study that enrolled adult patients with metastatic CRC.3 Patients were required to have experienced disease progression on or have been intolerant to trifluridine/tipiracil (Lonsurf) or regorafenib (Stivarga). Eligible patients also needed to have a body weight of at least 40 kg, an ECOG performance status of 0 or 1, measurable disease per RECIST 1.1 criteria, and an expected survival of over 12 weeks.

    Patients were randomly assigned 2:1 to receive fruquintinib (n = 461) or placebo (n = 230) at 5 mg daily, both in combination with best supportive care.1 Treatment was administered in 28-day cycles for 3 weeks on, 1 week off. Treatment in both arms continued until disease progression or unacceptable toxicity.

    The primary end point was overall survival (OS).3 Secondary end points included progression-free survival, objective response rate, disease control rate, duration of response, and safety.

    This retrospective analysis included CT scans from 221 patients enrolled in FRESCO-2; 442 lesions were analyzed from 162 patients in the fruquintinib arm and 167 lesions were analyzed from 59 patients in the placebo arm.1 For each lesion, 909 QVT features were extracted to quantify peritumoral vascularity. The longitudinal change in QVT features was calculated as the percentage change in features from screening to day 1 of cycle 3.

    Following CT scan image transfer, image processing and lesion selection occurred, followed by lesion annotation and segmentation. QVT features were then extracted and selected prior to data integration and analysis.

    The presence of lung metastases was the primary objective of the retrospective analysis. Notably, primary colorectal lesions were not analyzed due to the high rate of resection prior to screening.

    Additional Findings From the Retrospective Analysis

    Additional data from the retrospective analysis revealed that a statistically significant difference in Delta QVT with fruquintinib vs placebo was observed in 11 of the 21 preselected QVT features. Treatment with fruquintinib also showed a clear normalizing effect on tumor-associated vasculature in lung metastases. Compared with placebo, treatment with fruquintinib led to decreases in mean vessel curve intensity (P = .02095), mean branch length (P = .04677), number of branches (P = .01460), mean torsion (P = .01939), torsion length-to-distance ratio (P = .00991), number of vessel inflection points (P = .00606), mean vessel radius (P = .01282), and vessel volume (P = .00606).

    “These findings establish the value of QVT as a direct measure for fruquintinib-based antiangiogenic activity and support the use of this method as a potential tool to assess treatment effect based on the mechanism of action,” Lonardi and her coauthors wrote in their conclusion. “Further analyses are planned to include liver lesions and a predictive model of OS.”

    Disclosures: Lonardi reported being on the advisory boards of Amgen, Merck Serono, Lilly, Servier, AstraZeneca, MSD, Incyte, Daiichi-Sankyo, Bristol Myers Squibb, Astellas, GlaxoSmithKline, Takeda, Bayer, Rottapharm, BeiGene, Nimbus Therapeutics, and Helion. She has also been an invited speaker for Pierre Fabre, GlaxoSmithKline, Roche, Servier, Amgen, Bristol Myers Squibb, incyte, Lilly, Merck Serono, and AstraZeneca, as well as a coordinating primary investigator for Amgen, Merck Serono, Bayer, Roche, Lilly, AstraZeneca, and Bristol Myers Squibb.

    References

    1. Lonardi S, Yardibi O, Dasari A, et al. A novel imaging biomarker, quantitative vessel tortuosity, captures the antiangiogenic effect of fruquintinib in metastatic colorectal cancer. Presented at: ESMO Gastrointestinal Cancers Congress 2025; July 2-5, 2025; Barcelona, Spain. Abstract 32P.
    2. FDA approves fruquintinib in refractory metastatic colorectal cancer. FDA. November 8, 2023. Accessed July 4, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fruquintinib-refractory-metastatic-colorectal-cancer
    3. A study of efficacy and safety of fruquintinib (HMPL-013) in participants with metastatic colorectal cancer (FRESCO-2). ClinicalTrials.gov. Updated April 4, 2025. Accessed July 4, 2025. https://clinicaltrials.gov/study/NCT04322539

    Continue Reading

  • Xiaomi intros new affordable smart glasses with up to 11 days of battery life

    Xiaomi intros new affordable smart glasses with up to 11 days of battery life

    Xiaomi has introduced new smart glasses to the global market. The eyewear is called the Smart Audio Glasses and is currently available on AliExpress for $86.54. While that’s an affordable price tag, the feature set is not as extensive as some of the other options in the market.

    To be specific, as the name somewhat suggests, the wearable is basically a pair of glasses with functionalities of Bluetooth earbuds. Of course, given the design, these smart glasses can be considered an alternative to open-ear headphones, and as Xiaomi highlights, there are sound leakage protections for enhanced privacy in public spaces.

    The company also notes that the smart glasses feature an SLS0820 ultrasonic speaker and sound cavity structure algorithm. This combination allows the eyewear to offer “optimized sound quality” and deliver “rich, deep bass” along with “vibrant, clear treble.” The wearable has an echo-cancelling algorithm as well, which is said to lower distortion and ensure clear audio output.

    Another highlight of the Xiaomi Smart Audio Glasses is the battery life. The company claims that in standby mode, the runtime can reach 11 days, while they are said to offer up to 10 hours of battery life when listening to audio. Regarding charging the built-in battery, the wearable relies on a magnetic pogo pin charger, similar to what most smartwatches come with.

    Design-wise, Xiaomi highlights that the smart glasses have a frame that weighs 40 grams. With a comfort-forward temple curve and adjustable nose pads, the wearable is said to offer all-day comfort. Other highlights include a detachable hinge design for interchanging frames, an IP54 water and dust resistance rating, and touch controls.

    Continue Reading

  • All active Anime Vanguards codes (July 2025) | Esports News

    All active Anime Vanguards codes (July 2025) | Esports News

    Tower Defense is an immensely popular genre on Roblox, and there are several amazing titles like Anime Vanguards that you can play. In the game, you can essentially end up using the various anime-based characters to defend your base from the waves of enemies. Besides regularly obtaining items in Anime Vanguards, one of the finest methods that you can use is the codes that are released by the developers. These codes are easy to redeem and straight away provide the associated rewards. Here is a list of all the active Anime Vanguards codes that you can use for the freebies.

    Working Anime Vanguards codes (July 2025)

    Roblox Anime Vanguards

    Use the codes below to get free rewards (Image via Roblox)

    The following are the active Anime Vanguards codes that you can use to get your hands on free rewards inside the game:

    • Kat – A cat animation plays
    • PysephBirthday – 1x Flower
    • Spring – 1500x Flowers + 1500x Gems + 5000x Gold
    • Sorry4Bugs – 40x Rerolls + 20x Stat Chips
    • Late – 5x Phoenix Shards + 5x Elemental Shards

    You will be able to use them directly inside the game to get the aforementioned rewards. Please keep in mind that these codes have the tendency to expire after a set duration of time. As a result, you must redeem them before they expire. All the latest codes for Anime Vanguards can be found by following the game and the developers on their respective social media handles.

    Expired Anime Vanguards codes

    Here are the Anime Vanguards that have now ended up expiring and do not work anymore:

    • DELAY
    • FateUpdate
    • 500MVISITS
    • enumaelish
    • SEASONOFLOVE
    • YT200K
    • LATEUPDATESORRY
    • 100MVISITS
    • HALLOWEENWASLASTMONTH
    • 10KLIKES
    • HeavenOrHell
    • UntilThenIsTheBestGame
    • CORRUPTION
    • 600KLIKES
    • EXTENDEDMAINT
    • AURA
    • WECURSESHAVENOLIMITS
    • ALSISBEST
    • SLAYER
    • DOUBLEEVOLUTION
    • 1MILLION
    • DELAYGUARDS
    • BYEDIVALO
    • 800KLIKES
    • 300KLIKES
    • 10MVISITS
    • HAPPYNEWYEAR
    • ROST10K
    • AV50MIL
    • STEELBALL
    • THXFOR1MLIKES
    • LordShadow
    • 200KLIKES
    • PvP
    • 25MVISITS
    • PART7
    • 300KPLAYERS
    • SALTERBOSS
    • THESYSTEM
    • OneInAVanguardillion
    • SORRY4SHUTDOWN
    • WinterUpdateSoon
    • RELEASE
    • 100KLIKES
    • WHYISTHISNOTWORKING????????
    • 100kSubs
    • 2MLIKES
    • TIKTOK50K
    • ODYSSEYFIX
    • 400KLIKES
    • 23RDPRESIDENT
    • TURBONICLEGRANDMA
    • 70MVISITS
    • NewLobby!
    • STANDPROUD
    • UPDATE1
    • AV500KLIKES
    • LotsofPresents!
    • Update3!
    • SHIBUYA

    Steps to use Anime Vanguards codes

    Listed below are the steps that you can follow to utilize Anime Vanguards codes: The process is quite simple and would only take you a few minutes. Listed below are the steps that you can follow:

    1. Get started by opening Anime Vanguards on your device.
    2. Once the game is open, click on the “Codes” icon. This is located on the right side of the screen.
    3. A dialog box will appear, and you must enter the code in the text field.
    4. Finally, click on the “Redeem Code” button. The redemption process will be complete.

    You can then use the rewards to your benefit in Anime Vanguards.


    Continue Reading

  • UK’s Palestine Action loses bid to pause ban as ‘terrorist’ group | Israel-Palestine conflict News

    UK’s Palestine Action loses bid to pause ban as ‘terrorist’ group | Israel-Palestine conflict News

    London High Court upholds order that critics say puts the group’s anti-Gaza war protesters on a par with al-Qaeda, ISIL.

    Pro-Palestinian campaign group Palestine Action‘s cofounder has lost a bid to pause the British government’s decision to ban the organisation under “anti-terrorism” laws pending their legal challenge.

    Huda Ammori, who helped found Palestine Action in 2020, had asked London’s High Court to stop the proscription of Palestine Action as a “terrorist” organisation.

    On Friday, the High Court in London heard a challenge to the order and Judge Martin Chamberlain ruled against Ammori, meaning the proscription of Palestine Action is upheld and will come into force at midnight.

    Proscription would make it a crime to be a member of Palestine Action that carries a maximum sentence of 14 years in prison. Proscribed groups under British law include ISIL (ISIS) and al-Qaeda.

    After the parliamentary vote against the group on Wednesday, critics decried the chilling effect of the ban, which puts Palestine Action on a par with such armed groups.

    “Let us be clear: to equate a spray can of paint with a suicide bomb isn’t just absurd, it is grotesque. It is a deliberate distortion of the law to chill dissent, criminalise solidarity, and suppress the truth,” said independent British lawmaker Zarah Sultana.

    Palestine Action activists broke into a military base last month and sprayed red paint on two planes in protest at the UK’s support for Israel’s war on Gaza.

    Ammori’s lawyer Raza Husain said the proscription marked the first time the UK had sought to ban a group carrying out such direct action, describing it as “an ill-considered, discriminatory, authoritarian abuse of statutory power”.

    Palestine Action describes itself as “a pro-Palestinian organisation which disrupts the arms industry in the United Kingdom with direct action”. It says it is “committed to ending global participation in Israel’s genocidal and apartheid regime”.

    Home Secretary Yvette Cooper, the UK’s interior minister, has said that violence and criminal damage have no place in legitimate protest and her lawyers say the case should be brought at the Proscribed Organisations Appeal Commission instead.

    Rights groups have accused Israel of repeatedly committing abuses in its war in Gaza, which began on October 7, 2023. Since then, at least 57,268 Palestinians have been killed and 135,625 wounded, according to Gaza’s Health Ministry.

    Continue Reading

  • Human brain cells continue to form into late adulthood, study finds

    Human brain cells continue to form into late adulthood, study finds

    A study has shown that neurons or nerve cells continue to form well into late adulthood in the brain’s hippocampus, which manages memory—a finding that presents compelling new evidence about the human brain’s adaptability.

    Advertisement

    Neurogenesis—a process whereby new neurons are created—is said to continue throughout one’s life, even as the rate is considered to slow down with age.

    However, researchers from Karonlinska Institutet in Sweden said the extent and significance of neurogenesis is still debated with no clear evidence of cells that precede new neurons—or ‘neural progenitor cells’—actually existing and dividing in adults.

    “We have now been able to identify these cells of origin, which confirms that there is an ongoing formation of neurons in the hippocampus of the adult brain,” Jonas Frisen, professor of stem cell research, Karolinska Institutet, who led the research published in the journal Science.

    The team used carbon dating methods to analyse DNA from brain tissue, which made it possible to determine when the cells were formed. Tissue samples of people aged 0 to 78 were obtained from international biobanks, they said.

    The results showed that cells that precede the forming of new neurons in adults are similar to those mice, pigs and monkeys, with differences in genes which are active.

    The researchers also found large differences between individuals—some adult humans had many neural progenitor cells, others hardly any at all.

    Frisen added that the study is an “important piece of the puzzle in understanding how the human brain works and changes during life”, with implications for developing regenerative treatments in neurodegenerative and psychiatric disorders.

    A steady loss of neurons resulting in an impaired functioning and eventually cell death is said to drive neurodegenerative disorders, which affects the hippocampus, among other brain regions. Risks of the disorders are known to heighten with age.

    For the study, the researchers used a method called ‘single-nucleus RNA sequencing’, which looks at activity of a gene in a cell’s nucleus.

    This was combined with machine learning (a type of AI) to discern varied stages of how neurons develop, from stem cells to immature neurons, many of which were in the division phase, the team said.

    “We analysed the human hippocampus from birth through adulthood by single-nucleus RNA sequencing. We identified all neural progenitor cell stages in early childhood,” they wrote.

    “In adults, using antibodies against the proliferation marker Ki67 and machine learning algorithms, we found proliferating neural progenitor cells,” the authors wrote.

    “The results support the idea that adult neurogenesis occurs in the human hippocampus and add valuable insights of scientific and medical interest,” the study said.


    Continue Reading

  • Pakistan, Azerbaijan signs agreement for investment worth $2bln in diverse sectors of Pakistan's economy – RADIO PAKISTAN

    1. Pakistan, Azerbaijan signs agreement for investment worth $2bln in diverse sectors of Pakistan’s economy  RADIO PAKISTAN
    2. Azerbaijan signs $2 Billion investment agreement with Pakistan to deepen economic partnership  Ptv.com.pk
    3. Regional cooperation and technological advancement essential for shared prosperity: PM Shehbaz  Ptv.com.pk
    4. PM arrives in Azerbaijan to attend 17th ECO Summit  Dawn
    5. PM arrives in Azerbaijan for 17th ECO Summit  The Express Tribune

    Continue Reading